AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18435374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone application for 10 seconds after etching and 10 seconds after bonding using a 5 mm delivery cup.
Number of subjects: 60
Study 18435374 — intervention group
Group type: COMPARATOR
Intervention: Control group (not subjected to ozone).
Number of subjects: 60
Study 16518328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular ultrasound surveillance for graft stenosis every 4 months in addition to clinical monitoring
Number of subjects: 126
Study 16518328 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring alone
Number of subjects: 126
Study 16518328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular ultrasound surveillance for graft stenosis
Number of subjects: 126
Study 12768330 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPA-dGlu(1)-minigastrin
Number of subjects: 4
Study 12768330 — intervention group
Group type: COMPARATOR
Intervention: DTPA-Leu(1)-minigastrin
Number of subjects: 4
Study 10994679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 10994679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9180228 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tube drain with primary wound closure
Number of subjects: 23
Study 9180228 — intervention group
Group type: COMPARATOR
Intervention: Simple primary wound closure (no drain)
Number of subjects: 23
Study 1621496 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine sulphate
Number of subjects: 43
Study 1621496 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg fentanyl citrate
Number of subjects: 43
Study 1621496 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg meperidine hydrochloride
Number of subjects: 43
Study 1621496 — intervention group
Group type: COMPARATOR
Intervention: 2 ml saline
Number of subjects: 43
Study 2418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 0
Study 2418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicardipine
Number of subjects: 0
Study 2418306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30334981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 4%
Number of subjects: 0
Study 30334981 — intervention group
Group type: EXPERIMENTAL
Intervention: PCMX 3%
Number of subjects: 0
Study 30334981 — intervention group
Group type: COMPARATOR
Intervention: Propan-1-ol 60% (P-1)
Number of subjects: 0
Study 28544215 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth neck implant (1.5 mm)
Number of subjects: 93
Study 28544215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough neck implant with grooves
Number of subjects: 93
Study 28544215 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped rough neck implant with grooves
Number of subjects: 93
Study 28544215 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 93
Study 26629926 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose mannitol solution
Number of subjects: 6
Study 26629926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin solution (600 mg)
Number of subjects: 6
Study 26629926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid solution (500 mg)
Number of subjects: 6
Study 26629926 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant juice
Number of subjects: 6
Study 26629926 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 6
Study 26629926 — intervention group
Group type: EXPERIMENTAL
Intervention: Various solutions (lactulose mannitol, aspirin, ascorbic acid, blackcurrant)
Number of subjects: 6
Study 23489467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 160
Study 23489467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21399532 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + PRO (1% each of dextrose, fructose, and maltodextrin + 1.2% PRO)
Number of subjects: 14
Study 21399532 — intervention group
Group type: COMPARATOR
Intervention: CHO (6% dextrose only)
Number of subjects: 14
Study 21399532 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 14
Study 21399532 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 14
Study 18855810 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/day)
Number of subjects: 155
Study 18855810 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day)
Number of subjects: 155
Study 18855810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 16790039 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI) administered by trained nurses
Number of subjects: 361
Study 16790039 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 361
Study 16790039 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 361
Study 16790039 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation of MPI
Number of subjects: 361
Study 16790039 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation of MPI
Number of subjects: 361
Study 12681876 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 microg)
Number of subjects: 90
Study 12681876 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost (1 mg)
Number of subjects: 90
Study 11933303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimbus 3 alternating pressure mattress replacement system (APMRS)
Number of subjects: 32
Study 11933303 — intervention group
Group type: COMPARATOR
Intervention: Control surfaces (another APMRS in hospital, alternating pressure mattress overlay in nursing home)
Number of subjects: 32
Study 8888329 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mg/day transdermal nicotine
Number of subjects: 71
Study 8888329 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg/day transdermal nicotine
Number of subjects: 71
Study 8888329 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 mg/day transdermal nicotine
Number of subjects: 71
Study 8888329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 8888329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of nicotine replacement
Number of subjects: 71
Study 1511080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) 175-250 mg/day
Number of subjects: 0
Study 1511080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) + Lithium (Li) carbonate (serum level 0.5-0.9 mmol)
Number of subjects: 0
Study 1511080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6628802 — intervention group
Group type: EXPERIMENTAL
Intervention: Khellin treatment
Number of subjects: 10
Study 6628802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study 30249121 — intervention group
Group type: EXPERIMENTAL
Intervention: Live singing during hemodialysis (15 min for 6 sessions)
Number of subjects: 24
Study 30249121 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis
Number of subjects: 24
Study 29360560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine dual-responsive in situ gel (2% lidocaine)
Number of subjects: 0
Study 29360560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 27160246 — intervention group
Group type: EXPERIMENTAL
Intervention: icosabutate 600 mg once daily
Number of subjects: 140
Study 27160246 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 140
Study 24996489 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of controlled-release simvastatin 20 mg
Number of subjects: 122
Study 24996489 — intervention group
Group type: COMPARATOR
Intervention: Evening administration of immediate-release simvastatin 20 mg
Number of subjects: 122
Study 22913681 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (75 mg daily for 14 days)
Number of subjects: 292
Study 22913681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 22913681 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 292
Study 20353112 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-to-point needling
Number of subjects: 92
Study 20353112 — intervention group
Group type: COMPARATOR
Intervention: Perpendicular needling
Number of subjects: 92
Study 18158849 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich grapeseed extract (FRGSE)
Number of subjects: 23
Study 18158849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16316352 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid (AA) infusion
Number of subjects: 15
Study 16316352 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 15
Study 16316352 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD patients
Number of subjects: 15
Study 12525334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 12525334 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 11174571 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Diagnostic Criteria for Temporomandibular Disorders
Number of subjects: 163
Study 11174571 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI) diagnosis
Number of subjects: 163
Study 9202909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal midazolam (0.2 mg kg‐1, 5 mg ml‐1)
Number of subjects: 95
Study 9202909 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.3 mg kg‐1 in 5 mL saline)
Number of subjects: 95
Study 7962441 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (1.0 micrograms/ml)
Number of subjects: 14
Study 7962441 — intervention group
Group type: COMPARATOR
Intervention: Control (no progesterone)
Number of subjects: 14
Study 3688927 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 32
Study 3688927 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine
Number of subjects: 32
Study 31347696 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant time delay
Number of subjects: 27
Study 31347696 — intervention group
Group type: EXPERIMENTAL
Intervention: Most-to-least prompting
Number of subjects: 27
Study 31347696 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible prompt fading
Number of subjects: 27
Study 29458392 — intervention group
Group type: EXPERIMENTAL
Intervention: GP mail‐outs
Number of subjects: 0
Study 29458392 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement
Number of subjects: 0
Study 29458392 — intervention group
Group type: EXPERIMENTAL
Intervention: District nurse referrals
Number of subjects: 0
Study 29458392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Matters intervention
Number of subjects: 0
Study 29458392 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct contact with health professionals
Number of subjects: 0
Study 29458392 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondent‐driven sampling
Number of subjects: 0
Study 27576169 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation retreat
Number of subjects: 0
Study 27576169 — intervention group
Group type: COMPARATOR
Intervention: Relaxing on-site (vacation arm)
Number of subjects: 0
Study 27576169 — intervention group
Group type: COMPARATOR
Intervention: Regular meditators
Number of subjects: 0
Study 24786217 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioverter defibrillator-only therapy
Number of subjects: 714
Study 24786217 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐LVRR score (range, 0-7)
Number of subjects: 714
Study 24786217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 714
Study 23715050 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP‐Tacro once-daily
Number of subjects: 47
Study 23715050 — intervention group
Group type: COMPARATOR
Intervention: Prograf twice-daily
Number of subjects: 47
Study 20443101 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon alfa 2b (1.5 microg/kg/week) alone (group A)
Number of subjects: 40
Study 20443101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2b (1.5 microg/kg/week) with ribavirin (12-15 mg/kg/day; group B)
Number of subjects: 40
Study 18164145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Services (nurse-delivered manual-guided behavioral drug and HIV risk reduction counseling and abstinence-contingent take-home buprenorphine)
Number of subjects: 24
Study 18164145 — intervention group
Group type: COMPARATOR
Intervention: Standard Services (physician administered advice and support, and weekly, non-contingent medication pick-up)
Number of subjects: 24
Study 18164145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Services
Number of subjects: 24
Study 18164145 — intervention group
Group type: COMPARATOR
Intervention: Standard Services
Number of subjects: 24
Study 18164145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 16192247 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest CD4+ cell count <50 cells/mm3
Number of subjects: 432
Study 16192247 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load > or =100,000 copies/mL
Number of subjects: 432
Study 16192247 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest CD4+ levels
Number of subjects: 432
Study 16192247 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest viral load levels
Number of subjects: 432
Study 12645830 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (SFC) 50/100 microg twice daily
Number of subjects: 0
Study 12645830 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg twice daily plus oral montelukast (M) 10 mg once daily
Number of subjects: 0
Study 12645830 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (SFC)
Number of subjects: 0
Study 12645830 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) plus oral montelukast (M)
Number of subjects: 0
Study 10665126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous/oral trovafloxacin (300 mg i.v. alatrofloxacin switching to 200 mg oral trovafloxacin)
Number of subjects: 0
Study 10665126 — intervention group
Group type: COMPARATOR
Intervention: Intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid (1 g i.v. imipenem/cilastatin switching to 625 mg oral amoxycillin/clavulanic acid)
Number of subjects: 0
Study 8626943 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratio < 2
Number of subjects: 3404
Study 8626943 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratios between 2 and 3
Number of subjects: 3404
Study 8626943 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratios between 3 and 4
Number of subjects: 3404
Study 8626943 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratios between 4 and 5
Number of subjects: 3404
Study 8626943 — intervention group
Group type: EXPERIMENTAL
Intervention: International normalized ratios > 5
Number of subjects: 3404
Study 2054725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylamide (Orcolon)
Number of subjects: 137
Study 2054725 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 137
Study 2054725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 137
Study 31505974 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle of Progression (AOP)
Number of subjects: 221
Study 31505974 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Perineum Distance (HPD)
Number of subjects: 221
Study 31505974 — intervention group
Group type: EXPERIMENTAL
Intervention: AOP
Number of subjects: 221
Study 31505974 — intervention group
Group type: EXPERIMENTAL
Intervention: HPD
Number of subjects: 221
Study 30656870 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel Guided Discharge Plan (MGDP)
Number of subjects: 960
Study 30656870 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 960
Study 28669324 — intervention group
Group type: EXPERIMENTAL
Intervention: Determine™ Combo (DETE)
Number of subjects: 17
Study 28669324 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI™ (INSTI)
Number of subjects: 17
Study 27548757 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 82
Study 27548757 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 82
Study 27548757 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 82
Study 24973173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 FNA passes
Number of subjects: 62
Study 24973173 — intervention group
Group type: COMPARATOR
Intervention: 4 FNA passes
Number of subjects: 62
Study 21830844 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A)
Number of subjects: 10506
Study 21830844 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril + Hydrochlorothiazide (B+H)
Number of subjects: 10506
Study 20340049 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stay intensive care treatment (SSIC, 8 h of intensive care stay)
Number of subjects: 410
Study 20340049 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (care as usual, overnight intensive care stay)
Number of subjects: 410
Study 17157478 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 40
Study 17157478 — intervention group
Group type: COMPARATOR
Intervention: Lornoxicam 16 mg
Number of subjects: 40
Study 16382589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP Fast
Number of subjects: 90
Study 16382589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Molar Maxicap
Number of subjects: 90
Study 16382589 — intervention group
Group type: COMPARATOR
Intervention: Control (uncontaminated)
Number of subjects: 90
Study 16382589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin contaminated with saliva (Group 2)
Number of subjects: 90
Study 16382589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin contaminated, washed and air dried (Group 3)
Number of subjects: 90
Study 12423478 — intervention group
Group type: EXPERIMENTAL
Intervention: Music played to fetuses via headphone on maternal abdomen
Number of subjects: 20
Study 12423478 — intervention group
Group type: COMPARATOR
Intervention: Control group (headphone without sound)
Number of subjects: 20
Study 12423478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal music exposure
Number of subjects: 20
Study 10684124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed tea (3 g/day orally and 0.1% smeared on mucosa lesions three times a day for 3 months and 6 months)
Number of subjects: 36
Study 10684124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7657919 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (300 mg/day)
Number of subjects: 25
Study 7657919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2617212 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate 500 mg t.i.d. for 1 week
Number of subjects: 12
Study 2617212 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate 500 mg t.i.d. for 1 week
Number of subjects: 12
Study 2617212 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 12
Study 348537 — intervention group
Group type: EXPERIMENTAL
Intervention: Otocerol
Number of subjects: 106
Study 348537 — intervention group
Group type: COMPARATOR
Intervention: Cerumol
Number of subjects: 106
Study 31774037 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg per day for 12 weeks
Number of subjects: 13
Study 31774037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31273244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal AVP
Number of subjects: 0
Study 31273244 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 28714431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens cleaning paper patching
Number of subjects: 122
Study 28714431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 25689743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber AXOS (15 g)
Number of subjects: 0
Study 25689743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber FLAX (15 g)
Number of subjects: 0
Study 25689743 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber (4 g)
Number of subjects: 0
Study 25689743 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber isocaloric (LF-iso)
Number of subjects: 0
Study 23751992 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG plus ascorbic acid (PEG+Asc)
Number of subjects: 120
Study 23751992 — intervention group
Group type: COMPARATOR
Intervention: 4 L PEG plus simethicon (PEG+Sim)
Number of subjects: 120
Study 22126115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) program plus usual care
Number of subjects: 228
Study 22126115 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education program plus usual care
Number of subjects: 228
Study 22126115 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 228
Study 19447387 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) treatment
Number of subjects: 18645
Study 19447387 — intervention group
Group type: COMPARATOR
Intervention: Non-EPA treatment
Number of subjects: 18645
Study 17431702 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin therapy (40 g or 80 g within 24 h from symptom onset)
Number of subjects: 49
Study 17431702 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin therapy
Number of subjects: 49
Study 17431702 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 49
Study 14704548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.01%
Number of subjects: 120
Study 14704548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (latanoprost arm)
Number of subjects: 120